min. read
A group of drugs called immune checkpoint inhibitors can augment the anti-cancer effect of genetically engineered T cells. With support from The Faris Foundation, Texas Children’s Cancer Center is beginning the HEROS 3.0 trial, our most advanced clinical trial to date recurrent sarcomas, a type of cancer of the muscle or bone.
Related Stories
21521
Press Release
video